Table 1. Effect of different durations of treatment with eupatorin on cell cycle phase distribution of human leukemia cells.

		% Sub-G1	%G1	%S	G2-M
U937
6 h	Control	0.9±0.1	45.2±1.1*	22.9±0.4	30.1±1.3*
	Eupatorin	1.5±0.1	18.5±1.4*	26.4±0.3	52.7±1.3*
12 h	Control	0.5±0.1	45.8±0.8*	26.3±0.5*	26.1±0.4*
	Eupatorin	10.5±1.0*	19.0±2.0*	17.4±0.7*	51.6±1.1*
24 h	Control	1.2±0.4	46.9±0.5*	22.2±0.4*	28.2±0.3*
	Eupatorin	19.4±1.3*	35.7±1.7*	20.6±0.5*	21.2±1.0*
HL60
6 h	Control	6.7±0.3	44.5±0.7*	15.0±0.5	29.1±0.4*
	Eupatorin	8.6±0.5	32.3±0.9*	16.0±0.2	36.7±1.2*
12 h	Control	5.1±0.6	45.5±0.4*	18.0±0.3	27.7±0.2*
	Eupatorin	12.8±0.4*	32.2±1.1*	11.6±0.3	38.4±1.4*
24 h	Control	7.8±0.7	49.7±0.3*	17.9±0.2*	21.8±0.8
	Eupatorin	12.9±0.1*	42.2±0.4*	17.4±0.5*	21.9±0.8
Molt-3
6 h	Control	6.2±0.8	70.2±1.2	7.6±0.4	16.2±0.4
	Eupatorin	5.1±0.3	64.9±0.4*	9.6±0.3	21.1±0.4*
12 h	Control	9.1±1.4	70.7±1.7	7.2±0.3	7.2±0.2
	Eupatorin	13.3±1.7*	64.8±3.5	5.2±0.6	6.0±0.6
24 h	Control	7.1±0.2	70.2±0.5	6.5±0.3	13.4±0.2*
	Eupatorin	18.6±1.8*	67.9±1.7	4.0±0.2	7.2±0.4

Cells were cultured with 3 µM eupatorin for the indicated period of times and the cell cycle phase distribution was determined by flow cytometry. The values are means ± SE of three independent experiments with three determinations in each. Asterisks indicate a significant difference (P<0.05) compared with the corresponding controls.